Patients, families, and providers who treat individuals who have Alzheimer’s disease were likely encouraged to learn that lecanemab-irmb (Leqembi) received full approve from the Food and Drug Administration because of its potential to slow progress of the disease. Any excitement was soon tempered by warnings that the drug’s side effects could be severe, however—so much so that some patients (such as those on blood thinners) may not be candidates to take it at all. Some …
Read More









